|
Accession number;02A0472881
|
| Title;Genetic association between cytochrome P-450 2D6 polymorphism and risperidone plasma concentration. |
| Author;
MATSUBARA YOICHIRO
(Juntendodai I Koshigayabyoin Seishin'igaku)
SHIBATA NOBUTO
(Juntendodai I Koshigayabyoin Seishin'igaku)
ONUMA TOORU
(Juntendodai I Koshigayabyoin Seishin'igaku)
TAKAHASHI TADASHI
(Juntendodai I Koshigayabyoin Seishin'igaku)
KIMURA MICHIHIRO
(Juntendodai I Koshigayabyoin Seishin'igaku)
ARAI HEII
(Juntendodai I Koshigayabyoin Seishin'igaku)
|
Journal Title;Annual Report of the Pharmacopsychiatry Research Foundation
|
Journal Code:Y0939A
|
ISSN:0286-7591
|
|
VOL.;NO.34;PAGE.106-110(2002)
|
| Figure&Table&Reference;FIG.1, TBL.2, REF.4 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Risperidone is partly(>80%) metabolized by cytochrome P-4502D6(CYP2D6) which has over 20 genetic polymorphism. The purpose of this study is to investigate whether individual risperidone plasma concentration was affected by major oriental population mutation, CYP2D6*10A polymorphism or not. The genomic DNA from thirty-seven subjects who have been taking risperidone were analysed by restriction fragment length polymorphism(RFLP) method for the detection of CYP2D6*10A. The plasma concentrations of risperidone were measured by LC/MS/MS method. The "plasma concentration of risperidone" and "plasma concentration of 9-OH-risperidone" showed a strong correlation with the "risperidone dose/body weight" (r=0.56,p=0.0002;r=0.49,p=0.0018, respectively). The metabolic ratio, "risperidone/9-OH-risperidone concentration" showed no correlation with it(r=0.25,p=0.136). Neither any of plasma concentration nor metabolic ratio showed no correlation with CYP2D6*10A mutation. These results led us to the conclusion that the CYP2D6*10A mutation does not affects on individual risperidone plasma concentration but it may be useful to estimate the individual risperidone plasma concentration from its oral dose. (author abst.) |
|
|
|
Related Articles;
|
